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Stem cells have recently emerged as an important candidate for cell therapy. However, some major limitations still exist such as a
small quantity of cell supply, senescence, and insuﬃcient diﬀerentiation eﬃciency. Therefore, there is an unmet need to control
stem cell behavior for better clinical performance. Since native microenvironment factors including stem cell niche, genetic
factors, and growth factors direct stem cell fate cooperatively, user-speciﬁed in vitro settings are required to understand the
regulatory roles and eﬀects of each factor, thereby applying the factors for improved cell therapy. Among others, various types
of biomaterials and transfection method have been employed as key tools for development of the in vitro settings. This review
focuses on the current strategies to improve stemness maintenance, direct diﬀerentiation, and reprogramming using
biomaterials and genetic factors without any aids from additional biochemicals and growth factors.
1. Introduction
Stem cell therapy possesses signiﬁcant advantages com-
pared to conventional cell therapy using mature cells, as
stem cells are more accessible and obtainable, are easy to
culture and expand, and enable avoiding graft-versus-host
rejection [1–3]. With such merits, stem cells have emerged
as a candidate for cell therapy since 1968 when bone marrow
transplantation surgery was conducted. Stem cells can self-
renew and further diﬀerentiate into speciﬁc lineages upon
stimulation. Among many kinds of stem cells, adult stem
cells, represented by mesenchymal stem cells (MSCs), can
be isolated or derived from many kinds of tissues and thus
possess similar but diﬀerent properties from each other. In
a native microenvironment, MSCs are surrounded by stem
cell niches composed of extracellular matrix (ECM) and
growth factors. These microenvironment factors play
instructive roles in directing stem cell behavior such as
growth, lineage commitment, and stemness maintenance.
For clinical applications, stem cells have to be expanded
because only a limited number of cells can be extracted from
a tissue source. Moreover, when stem cells are expanded in a
series of exhausted in vitro culture, the eﬃcacy of their pro-
liferation and diﬀerentiation decreases due to a progressive
loss of stemness driven by senescence. To overcome such
problems, state-of-the-art technologies using biomaterials,
genetic factors, and growth factors which can mimic a native
microenvironment or improve stem cell behavior have been
employed recently. In conventional studies, various growth
factors or cytokines were pretreated to stem cells during
in vitro cultivation to induce a speciﬁc direction of diﬀeren-
tiation for transplanting in a damaged tissue [4]. For exam-
ple, ﬁbroblast growth factor 2 (FGF2) has been reported to
enhance MSC proliferation [5, 6]. The pretreated cells with
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growth factors, such as bone morphogenetic proteins
(BMPs) or transforming growth factor β (TGF-β), can pro-
mote MSCs to diﬀerentiate into osteoblast or chondrocyte
in vitro and induce eﬃcient bone formation and cartilage
regeneration compared to no treatment control [7–10].
However, FGF2 treatment is not able to overcome cellular
senescence and the loss of diﬀerentiation potential of MSCs
[11]. Moreover, because of the short half-life of growth fac-
tors, a large amount of growth factors is required to achieve
the goal, resulting in high cost. Also, direct injection of
growth factors may cause serious side eﬀects such as osteo-
phyte formation, swelling, and synovial hyperplasia [9].
Because of such disadvantages of growth factor treatment,
applying biomaterials (e.g., natural, synthetic), biophysical
factors (e.g., ultrasound), or biochemical factors (e.g., gene
transfection) have emerged as alternative encouraging strat-
egies to control stem cell fate.
Here, we review the current strategies to control stem cell
fate using biomaterials, physiochemical factors, and genetic
factors (Figure 1) in the absence of growth factor treatment.
We ﬁrst reviewed the strategies for stemness maintenance
of adult stem cells using physiochemical factors (Table 1)
and biomaterials (Table 2). Next, we introduced various
types of biomaterials which can help adult stem cells to
induce diﬀerentiation into speciﬁc lineages (Table 3). Finally,
we reviewed genetic reprogramming methods for induced
pluripotent stem cells (iPSCs) (Tables 4 and 5).
2. Improvement of MSC Stemness Using
Biophysical Stimulation, Organic
Compounds, and Biomaterials
Adult stem cells, represented by MSCs, are considered as an
attractive agent for cell therapy because of their ability to
self-renew and diﬀerentiate into various tissue cell types
[12, 13]. However, the cell number when isolated is not
usually suﬃcient for clinics. Therefore, a series of in vitro
expansion of stem cell is indispensable. As MSCs lose their
self-renewing ability and diﬀerentiation capacity during sub-
culturing, maintenance of stemness has become an essential
requirement for a successful stem cell therapy [14, 15]. Here,
we review biophysical stimulation (Table 1), organic com-
pound treatment (Table 1), and biomaterials (Table 2) as
major methodological factors to maintain mature and homo-
geneous diﬀerentiation of stem cells [16, 17].
2.1. Biophysical Stimulation. Biophysical stimuli are one of
important factors to enhance the diﬀerentiation capability
of MSCs, for example, when a normal human cartilage was
continuously exposed to physical pressure, such as joint load-
ing. This stimulus went through cell membranes, thereby
playing a pivotal role in structural maturation of cartilage.
As another example, when MSCs were subjected to low-
intensity pulsed ultrasound (LIPUS) stimuli in vitro, the cells
diﬀerentiated into chondrocytes. Furthermore, when chon-
drogenic diﬀerentiation was induced in alginate, LIPUS-
stimulated MSCs were not dediﬀerentiated even though the
culture environment was not suitable for chondrogenic
diﬀerentiation [18]. Along the same line, when MSCs were
transplanted with PGA scaﬀold in a defect site post-LIPUS
exposure for a week, the tissue morphology was maintained
like an intact cartilage [19]. Another study demonstrated
that when MSCs were stimulated with ultrasound, osteo-
genic diﬀerentiation was reduced compared to control MSCs
[20, 21]. This result suggests that biophysical stimulation has
signiﬁcant eﬀects on MSCs to keep the undiﬀerentiated or
diﬀerentiated status.
2.2. Biochemical Stimulation. MSCs express important plu-
ripotent factors including Oct4, Sox2, Nanog, and cMyc,
and these factors have been widely studied. However, expres-
sion of these factors reduces when MSCs undergo cell senes-
cence during a series of subculture [22–24]. To address this
issue, overexpression of pluripotent factors through lentiviral
transfection was studied, thereby enhancing the self-renewal
and diﬀerentiation potential of MSCs [25]. In addition to
pluripotent factors, the telomere activity was found to reduce
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Figure 1: Strategies employing biomaterials and genetic factors to control stem cell fate. Stem cells can either maintain stemness, diﬀerentiate
into speciﬁc lineages, or be reprogrammed to iPSCs.
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during in vitro cultivation. Thus, sirtuin 1 (SIRT1: a class III
histone deacetylase protein) was treated to induce expression
of telomerase reverse transcriptase (TERT) [26]. Sirt1 is also
known as an important factor which regulates the lifespan,
aging, metabolic homeostasis, and age-associated senescence
of MSCs by controlling Sox2 acetylation [27].
In order to develop a better strategy to reduce cell
senescence or to improve stemness, organic compounds
are treated to MSCs to prevent the decrease of pluripotent
marker expression. For example, since resveratrol is an
antioxidant as well as Sirt1 activator, its treatment improved
the stability of Sox2 by preventing acetylation and degrada-
tion of Sox2 [27]. Moreover, sustained treatment of resvera-
trol during ex vivo expansion maintained self-renewal and
diﬀerentiation capacities from an early passage until a late
passage [28]. These results suggest that treating stem cells
with antioxidants can be a reliable option to maintain MSC
stemness during subculture.
Another major cause of cell senescence is intracellular
accumulation of reactive oxygen species (ROS) [29] (“oxida-
tive stress”) which results in aging with end point apoptosis
of MSCs [30, 31]. Nuclear factor (erythroid-derived 2)-like
2 (NRF2) plays a vital role in defending against oxidative
stress at the cellular level. Therefore, conservation of NRF2
nuclear localization is important to overcome MSC aging
during subculture [32, 33]. A previous study reported that
treatment of t-BHQ, an antioxidant, increased translocation
of NRF2 into the nucleus and prevented cellular senescence
by regulation of the p53-Sirt1 axis, as p53 can suppress the
transcriptional activity of Sirt1 by binding to the Sirt1 pro-
moter [34]. Due to such changes in cellular behaviors under
t-BHQ treatment, aged cells elevated the abilities for self-
renewal and osteogenic diﬀerentiation [35]. Together, the
results suggest that antioxidant treatment is a promising
approach to reduce cell senescence especially in long-term
culture for a successful MSC therapy in vivo.
2.3. Biomaterials. The extracellular matrix (ECM) controls
stem cell fate (e.g., proliferation and diﬀerentiation) through
integrin-receptor binding [36, 37]. Therefore, a series of bio-
materials have been employed due to user-deﬁned tunability
of cell-matrix interaction (e.g., cell adhesion and cytoskel-
etal tension) as an artiﬁcial matrix platform. In this part,
we introduce major types of biomaterials which have been
used to maintain or to enhance stemness of adult stem
cells, especially MSCs.
Biomaterials can be categorized into natural or synthetic
materials in general. Among natural biomaterials, decellular-
ized ECMs have been studied to control stem cell behavior
recently. For example, the ECM where naive human MSCs
(hMSCs) resided was decellularized and used for in vitro cul-
ture. This culture substrate was found to maintain stemness
of human or mouse-derived adult stem cells most likely
because it provided an in vivo-like stem cell niche [38–41].
Also, decellularized tendon tissue was found to maintain
stemness and thereby promoted tenocyte diﬀerentiation of
human tendon stem cells (hTSCs) by providing an amiable
niche [42].
In addition to natural biomaterials, synthetic biomate-
rials have been recently designed to maintain or enhance
stemness. For example, encapsulation of MSCs into hydro-
gels can mimic the three-dimensional microenvironment of
Table 1: Maintenance of stemness using biophysical and biochemical stimulations.
Type of stimulation Details of condition Type of cells Observation Ref.
Biophysical
stimulation
Low-intensity pulsed
ultrasound (LIPUS)
hMSCs
hMSCs diﬀerentiated into chondrocyte without
dediﬀerentiation in nonchondrogenic diﬀerentiation
environments.
[18]
LIPUS hMSCs
The transplanted cells diﬀerentiated into chondrocytes
and regenerated defect sites of recipient cartilage.
[19]
Ultrasound hMSCs
Ultrasound treatment enhanced fracture healing by
promoting osteogenic diﬀerentiation of hMSCs.
[20]
Fluid ﬂow
Osteocyte,
osteoblast,
and hMSCs
Flow stimulation promoted recruitment, proliferation,
and diﬀerentiation of osteoprogenitor cells.
[21]
Overexpression
of genetical factor
SRY- (sex-determining
region Y-) box 2 (SOX2)
Sirtuin 1 (SIRT1)
hMSCs
Overexpression of Sox2 enhanced stemness of MSCs
during in vitro cultivation.
[23]
hMSC
Overexpression of SirT1 prevented age-associated
senescence of MSCs via Sox2 regulation.
[26, 27]
Octamer-binding
transcription factor 4 (Oct4)
or pron. nanOg (Nanog)
hMSC
Viral transfection of Oct4 or Nanog enhanced the
self-renewal and diﬀerentiation potential of MSCs.
[24, 25]
Treatment of
organic compound
Resveratrol hMSCs
Resveratrol treatment enhanced maintenance of the
self-renewal and diﬀerentiation capacity of MSCs
during ex vivo cultivation.
[28]
Nuclear factor erythroid-
derived 2-like 2 (NRF2)
hMSCs
Treatment of t-BHQ, the activator of NRF2, promoted
self-renewal ability and osteogenic diﬀerentiation
via inhibition of p53 expression.
[35]
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native tissues. Polyacrylamide, alginate/GelMA, or pullulan-
collagen hydrogels with low stiﬀness maintained stemness
because they helped with the maintenance of low cytoskel-
etal tension [43–45]. Also, decreasing the cell matrix-
binding aﬃnity by reducing the Arg-Gly-Asp (RGD) density
is revealed to enhance stemness in poly(carboxybetaine)
hydrogels [46].
Besides, surface topography is a common method to
control cell behavior related to stemness. While MSCs
were cultured on nanopatterned poly(ε-caprolactone) (PCL)
substrates with 120nm pits in a square arrangement with
a centre-centre spacing of 300nm, stemness was enhanced
[47]. On the other hand, nanotopography with an aligned
shape (polydimethylsiloxane, 250 nm in depth, 350nm in
width, and with 700nm pitch) did not enhance MSC stem-
ness compared to a nontopographic surface [48].
Polymeric surface coating serves as another promising
option to control stemness. Poly-L-lysine (PLL) is a widely
Table 2: Maintenance of stemness using biomaterials.
Type of biomaterials Details of materials Type of cells Observation Ref.
Natural
(nonsynthetic)
Decellularized ECM of
undiﬀerentiated hMSCs
hMSCs
mASCs
Decellularized ECM of undiﬀerentiated MSCs promoted
self-renewal, colony formation, and stemness maintenance
of hMSCs.
[38–41]
Decellularized
tendon tissue
hTSCs
Decellularized tendon tissues enhanced self-renewal and
stemness maintenance of hTSCs.
[42]
Hydrogel
Polyacrylamide gels
and PDMS stamps
hMSCs
Low cytoskeletal tension was maintained by controlling
substrate stiﬀness as cell spreading was restricted, thereby
enhancing stemness. Polyacrylamide gels and PDMS stamps
were used to regulate biophysical parameters.
[43]
Alginate/GelMA
hydrogels
hBMSCs
and
GMSCs
Compared to alginate hydrogels, alginate/GelMA hydrogels
maintained stemness due to decreased hydrogel stiﬀness.
[44]
Pullulan-collagen
hydrogel
mBMSCs
Biomimetic hydrogel maintained stemness of mouse bone
marrow-derived MSCs (mBMSCs) compared to tissue plate
culture, resulting in enhanced viability after in vivo injection.
[45]
RGD-modiﬁed
poly(carboxybetaine)
hydrogel
hBMSCs
hMSCs formed 3D spheroids on the 5 μM RGD substrate,
and the stemness was well maintained compared to 5mM
RGD substrate, which enhanced osteogenic diﬀerentiation.
[46]
Topography
PCL hMSCs
A surface nanopattern with 120 nm pits in a square arrangement
with a center-center spacing of 300 nm enhanced stemness of
hMSCs compared to the ﬂat PCL surface.
[47]
PDMS hBMSCs
A PDMS nanopattern 250 nm in depth, 350 nm in width, and
with 700 nm pitch decreased hBMSC stemness compared to
the ﬂat surface control.
[48]
Polymeric
surface
coating
PLL-coated surface
hBMSCs
PLL-coated surface improved proliferation but retarded the
replicative senescence of hBMSCs by increasing the S-phase.
[49]
hHSCs
PLL substrates increased the total number of hHSCs while
stemness was maintained.
[50]
PCL nanoﬁber hMSCs
Bone marrow collagen-mimetic PCL nanoﬁber matrices
increased the expression of self-renewal factors and cell-cell
interaction markers in hMSCs.
[51]
PEG-PCL copolymer hMSCs
PEG-PCL copolymer exhibited moderate surface repellency
and induced aggregation of hMSCs, which promoted stemness
and lowered intracellular ROS accumulation.
[52]
Nanoﬁbrous
scaﬀold
Emu oil-loaded
PCL/Coll nanoﬁber
hASCs
Emu oil-loaded nanoﬁbers with higher tensile strength
enhanced the expression of stemness, proliferation, and cell
adhesion markers in hASCs compared to unloaded nanoﬁbers.
[53]
Gelatin nanoﬁber hMSCs
3D culture of hMSC in a nanostructured electrospun gelatin
patch maintained stemness of hMSCs for 3 weeks.
[54]
Chitosan
Chitosan ﬁlm hASC
The chitosan ﬁlm induced spheroid formation of hASCs with
higher activities of self-renewal and colony formation, as well
as signiﬁcant upregulation of pluripotency marker expression.
[56]
Chitosan ﬁlm + hypoxia hUCBMSC
The chitosan ﬁlm promoted spheroid formation of hUCBMSC
under hypoxia than normoxia. HIF-1 additionally induced
expression of stemness genes.
[57]
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Table 3: Direct diﬀerentiation using biomaterials.
Property
Type of
materials
Diﬀerentiation Details of materials Comments Ref.
Composition
Scaﬀold
Chondrogenesis Cellulose/silk blend
Growing MSCs on a speciﬁc blend
combination of cellulose and silk in a
75 : 25 ratio signiﬁcantly upregulated
expression of chondrogenic markers.
[120]
myogenesis
ECM-like porous scaﬀold of
poly(3-hydroxybutyric acid-co-3-
hydroxyvaleric acid) (PHBHV)/
gelatin blends
PHBHV/gelatin constructs mimicking
myocardial structural properties.
[121]
Chondrogenesis/
osteogenesis
Collagen-glycosaminoglycan
Collagen-chondroitin sulphate (CCS)
scaﬀolds enhanced osteogenesis while
collagen-hyaluronic acid (CHyA)
scaﬀolds enhanced chondrogenesis.
[122]
Cardiomyogenesis
Carbon nanotube/poly-L-
lactide acid (PLA) nanoﬁber
The two-pronged carbon nanotube
template provided a biomimetic
electroactive cue, thereby directing
MSC diﬀerentiation.
[13]
Decellularized
tissues
Chondrogenesis
Cartilage extracellular matrix-
derived particles (CEDPs)
Microtissue aggregates (BMSCs and
CEDPs (263± 48 μm) cocultured in a
rotary cell culture system) showed a
more rapid restoration of joint
functions with superior cartilage repair
compared to the control groups in vivo.
[3]
Osteogenesis
Calcium phosphate nanoparticles
and demineralized bone matrix
(DBM) particles incorporated
into injectable polyHIPE
PolyHIPE compositions with BMSCs
promoted osteogenic diﬀerentiation
through upregulation of bone-speciﬁc
marker expression compared to a time
zero control.
[4]
Bioinorganics Osteogenesis 3D graphene foams (GFs)
3D GF culture platforms maintained
stem cell viability and promoted
osteogenic diﬀerentiation.
[123]
Biomimetics Chondrogenesis
Polyacrylate substrate functionalized
with RGD peptide
Biomimetic polyacrylate substrates
can direct chondrogenic diﬀerentiation
of mMSCs, hMSCs, and mouse KSCs
in the absence of exogenous TGF-bs.
[124]
Substrate
stiﬀness
Hydrogels
Osteogenesis/
neurogenesis
Polyacrylamide (0.5~40 kPa)
hydrogel substrate
MSCs on soft (~0.5 kPa) gels promoted
expression of neurogenesis markers while
MSCs on stiﬀ (~40 kPa) substrates
elevated expression of osteogenesis
markers. Transfer of MSCs from soft
to stiﬀ or stiﬀ to soft substrates led to a
switch in the lineage speciﬁcation.
[60]
Osteogenesis/
chondrogenesis
Methyl acrylate/methyl
methacrylate (18–72MPa)
hydrogel substrate
Both chondrogenic and osteogenic
markers were elevated when MSCs
were grown on substrates with
stif fness < 10MPa.
MSCs on lower stiﬀness gels express
elevated chondrogenesis markers while
MSCs on the higher stiﬀ substrates
express elevated osteogenesis markers.
[61]
Angiogenesis
Gelatin hydrogel conjugating
enzymatically cross linkable
hydroxyphenyl propionic acid
(GHPA)
GHPA as a promising soluble factor-free
cell delivery template induced endothelial
diﬀerentiation of MSCs with robust
neovasculature formation with favorable
host responses.
[63]
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used polymer as a surface coating material, because it
improves proliferation but retards replicative senescence by
increasing the S-phase population of MSCs [49] and hemato-
poietic stem cells (HSCs) [50] in the cell cycle. Also, coating
the culture substrate with PCL nanoﬁbers which can mimic
the size and shape of collagen ﬁbers of ECM is also known
to maintain stemness [51]. As another approach, poly(ethyl-
ene glycol)-poly(ε-caprolactone) (PEG-PCL) copolymers
were used to control surface repellency by altering the molar
percentage or chain length of PEG. This surface repellency
induced aggregation of hMSCs by upregulation of cell-cell
interaction proteins such as connexin-43, which further
increased stemness with a signiﬁcant decrease in intracellular
ROS accumulation (Figure 2) [52].
Furthermore, nanoﬁbrous scaﬀolds provided a 3D
microenvironment to stem cells and thus enhanced stem-
ness. For example, ASCs displayed an improved adhesion
capacity with high rates of bioactivity and proliferation when
cultured on emu oil-loaded nanoﬁbers [53]. Mesenchymal
stem cells (MSCs) showed a superior diﬀerentiation capacity
towards typical mesenchymal lineages when grown in a
nanostructured electrospun gelatin patch [54]. Especially,
emu oil exhibited a free radical scavenging activity, thereby
enhancing stemness [55].
Finally, a chitosan ﬁlm induced spheroid formation and
triggered a cell-cell interaction of hASCs, thereby enhancing
stemness. After spheroid formation, the spheroid-forming
hASCs expanded eﬃciently, formed a colony, and upregu-
lated the expression of pluripotency marker genes compared
to the monolayer-cultured control condition [56, 57].
In conclusion, the aforementioned types and formats of
biomaterials were found to enhance or maintain stemness.
We summarize the three major mechanisms by which the
biomaterials enhanced or maintained stemness as follows:
(1) reduction of cytoskeletal tension by reducing matrix stiﬀ-
ness, (2) spheroid formation by reduction of integrin-binding
sites and consequent promotion of cell-cell interaction, and
(3) antioxidative eﬀects by radical scavenging activity. These
strategies have potential to eﬀectively improve stemness of
MSCs in various biomaterial formats.
3. Direct Differentiation of MSCs
Using Biomaterials
While most methods known to induce mesenchymal line-
age diﬀerentiation of MSC depend on exposure to one or
more soluble growth factors, a growing body of evidence
suggests that it is possible to control MSC diﬀerentiation in
the absence of soluble factors. MSCs exhibit the ability to
diﬀerentiate towards speciﬁc lineages through biomaterials
with modiﬁcation of mechanical or biochemical properties,
matrix composition, topography, and surface stiﬀness. This
Table 3: Continued.
Property
Type of
materials
Diﬀerentiation Details of materials Comments Ref.
Angiogenesis PEGylated ﬁbrin 3D matrix
Endothelial diﬀerentiation of MSC
was induced by the 3D PEGylated
ﬁbrin matrix.
[64]
Surface
topograpy
Film
Neurogenesis/
myogenesis
Micropatterned poly(lactic-co-
glycolic acid) (PLGA) ultrathin ﬁlm
Micropattering: microsize lanes of 20 μm
width separated by 40 μm wide grooves
on a PLGA ultrathin ﬁlm (16.3± 1.5 μm)
[66]
Hydrogel
Adipogenesis/
neurogenesis
Hydrazine-treated polyacrylamide
gel (circular and anisotropic
geometry)
Cells cultured in small circular islands
show elevated expression of adipogenesis
markers while cells that spread in
anisotropic geometries elevated
expression of neurogenic markers.
[67]
Bioinorganics
Osteogenesis/
neurogenesis
Graphene/electrical stimulation
Speciﬁc combinations of nonbiological
inputs—material type, electrical
stimulation, and physical patterns on
graphene substrates regulated hMSC
lineage speciﬁcation.
[70]
Osteogenesis
Nanotubule-shaped titanium
oxide surface
Small (30 nm diameter) nanotubes
promoted cell adhesion without
noticeable diﬀerentiation, whereas larger
(70 to 100 nm diameter) nanotubes
elicited a dramatic stem cell elongation
(10-fold increased), which induced
cytoskeletal stress and selective
diﬀerentiation into osteoblast-like cells.
[71]
Osteogenesis Titanium substrate
Surface microstructure and surface
energy from microstructured Ti
substrate were able to direct osteogenic
diﬀerentiation of mesenchymal stem cells.
[72]
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approach would simplify the tissue engineering procedure
and be cost-eﬀective. Here, we summarize recent studies
that employed such approaches to induce direct diﬀerenti-
ation of MSC via biomaterial technologies (Table 3).
3.1. Composition. Collagen and glycosaminoglycan (GAG),
major components of natural ECM, play a key role in osteo-
chondral regeneration. Hence, their combined (CG) scaﬀolds
have been used successfully in tissue engineering applications
for regeneration of cartilage and bone [57, 58]. A previous
study reported the eﬀect of the composition and stiﬀness of
collagen and GAG scaﬀolds composed of chondroitin sul-
phate (CS) and hyaluronic acid (HA) on MSC diﬀerentiation
[59]. The study showed that the lowest stiﬀness (0.5 kPa) of
the CG scaﬀold facilitated chondrogenesis, while the stiﬀest
(1.5 kPa) scaﬀold induced osteogenesis. This was the ﬁrst evi-
dence proving that osteochondral diﬀerentiation of MSC
could be directed via scaﬀold composition using CG and fur-
ther enhanced by the GAG type. When cellulose, another
abundant natural polymer, was blended with silk at diﬀerent
compositions, growth and chondrogenesis of MSC were
Table 4: iPSC reprogramming and type of gene transfection.
Type Advantages Disadvantages
Transgene
expression
Eﬃciency Ref.
Virus
Adenovirus
Nonintegrative; infects
dividing and nondividing cells
Low eﬃciency No 0.0001~0.01% [84, 85]
Lenti/retrovirus
Ease of handling with
experience; medium–high
eﬃcacy
Integration of foreign DNA
into genome; residual expression
of reprogramming factors;
controversy regarding tumor
formation
Yes 0.1~1% [73, 125]
Sendai virus
Medium–high eﬃciency;
nonintegrating; robust
protein-expressing property;
wide host range
Involve viral transduction No 0.5~1.0% [88, 89]
Plasmid vector
Episomal
Nonintegrative; simple to
implement to laboratory
setup; less time-consuming
Very low eﬃciency; the use
of potent viral oncoprotein
(SV40LT antigen)
No 3–6× 10− 6 [87, 126]
Minicircle
More persistent transgene
expression; lack bacterial origin
Very low eﬃciency No 0.01% [127]
miRNA
Relative high eﬃciency;
nonintegration; easily
automated, making it an
exciting candidate for
routine biomanufacture.
Requires high gene dosages
and multiple transfections;
daily transfection; controversy
in reproducibility and mitigating
cost eﬀectiveness
No 1.4~2% [128, 129]
PiggyBac
transposons
Elimination of insertional
mutagenesis; no footprint
upon excision; higher genome
integration eﬃciency
Ineﬃcient excision, potential
for genomic toxicity
Excision with
transposase
0.1~1% [80]
Protein
Free of genetic materials;
direct delivery of reprogramming
factor proteins
Slow kinetics, low eﬃciency;
diﬃculties in generation and
puriﬁcation of reprogramming
protein
No 0.005~0.001% [130]
Small molecules
Ease of handling; no requirements
for reprogramming factors
More than one target, toxicity No 0.3~0.5% [86]
Table 5: iPSC reprogramming and donor cell type.
Donor cell type Ref.
Adipose-derived stem cells [131]
Amniotic ﬂuid [132]
Blood cell cord blood stem cells [104]
B lymphocytes [133]
Bone marrow cells [134]
Cardiac myocytes [135]
Dental pulp [136]
Dermal ﬁbroblasts [137]
Endometrial stromal ﬁbroblasts [100]
Hematopoietic progenitor cells [138]
Hepatocytes [139]
Keratinocytes (from hair pluck) [101]
Pancreatic β-cells [140]
Peripheral blood mononuclear cell [126]
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promoted [60]. This was also the ﬁrst report demonstrating
the potential of cellulose to induce chondrogenic diﬀerentia-
tion of MSC.
Recent studies investigated whether chondrogenic diﬀer-
entiation of MSC could be directed by biomimetic or decellu-
larized tissue-derived materials. Biomimetic polyacrylate
substrates functionalized with the RGD integrin-binding
peptide promoted chondrogenesis of MSC in the absence of
any soluble growth factors [61]. They suggested that the
amount of surface amine residues from the RGD peptide
was a key regulator to inducing the diﬀerentiation. Several
studies demonstrated that ECM components derived from
the cartilage promoted chondrogenesis of MSC [62–64]. In
all cases, however, the use of chondrogenic growth factors
was found to be essential for MSC chondrogenesis with
deposition of necessary matrix components. In addition, a
study reported that novel particles derived from natural car-
tilage ECM induced chondrogenic diﬀerentiation of MSC
even in the absence of TGF-β when the particles were used
as a cell carrier [65].
Calcium phosphate- (CaP-) based ceramics play a sig-
niﬁcant role in bone repair due to their osteoconductive
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potential for ﬁlling lost bone volumes, when CaP nanopar-
ticles and demineralized bone matrix (DBM) were fabricated
as an injectable bone graft by incorporating polymerized
high internal phase emulsions (polyHIPEs). This injectable
bone graft was found to induce direct osteogenesis of MSC
[58]. On the other hand, our recent study investigated the
potential of 3D graphene substrates to induce spontaneous
osteogenesis of MSC without additional stimuli [59]. These
reports revealed that material-derived cues were able to
guide MSC diﬀerentiation to osteogenesis in the absence
of extrinsic biochemical inputs.
Proper regeneration of the myocardium is dependent on
scaﬀold properties and thus can be enhanced by mimicking
features of the myocardial ECM. A three-hydroxybutyrate
and 3-hydroxyvalerate (PHBHV)/gelatin construct mimick-
ing the myocardial ECM structure was developed to promote
cardiac diﬀerentiation of MSC and cardiac resident cells
without any chemical stimulation [66]. This study demon-
strated that when speciﬁc physicochemical properties with
a microtopograph were produced to mimic the structural
and mechanical properties of myocardium in the PHBHV/
gelatin construct, myogenesis of the stem cells was promoted.
Electroconductive carbon nanotubes (CNT) demonstrated
an ability to induce myogenic diﬀerentiation of MSC in the
absence of additional stimuli [67]. Although the exact mech-
anism of this result is unclear, it was suggested that electrical
stimulation of MSC by culturing on the CNT-based polylac-
tic acid scaﬀold was a key factor to enhancing diﬀerentiation
to cardiomyocytes.
3.2. Substrate Stiﬀness. Among the biophysical cues that were
identiﬁed to regulate cell fate in static in vitro cultures, stiﬀ-
ness of culture substrates was suggested ﬁrst as a key property
in several important studies [60–64]. An increased stiﬀness
of the culture substrate was found to induce osteogenic dif-
ferentiation of MSCs [60, 61]. The role of matrix stiﬀness in
directing lineage speciﬁcation of MSCs was examined on
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(MA/MMA) polymer substrate with varying elastic modu-
lus [60]. This study demonstrated that the substrate group
with lower stiﬀness induced chondrogenesis of MSCs while
the substrate with rigid stiﬀness induced osteogenic speciﬁ-
cation of MSCs. Although its speciﬁc mechanism is unclear,
this study revealed that integrin β1 played a critical role in
this process. Cells sense their mechanical microenvironment
via integrin-ligand interactions which form focal adhesions
and thereby regulate intracellular signaling [65]. Another
study supported this ﬁnding [61] by showing that the soft
(~0.5 kPa) substrate was eﬀective in promoting neurogen-
esis of MSCs whereas the stiﬀ (~40pKa) one was eﬀective
in promoting their osteogenesis. Switching the biophysical
microenvironment of MSCs from soft to stiﬀ or stiﬀ to
soft substrates led to rewiring the two directions of MSC
lineage speciﬁcation.
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Although the diﬀerentiation potential of MSCs into
endothelial cells (ECs) remains unclear [68, 69], some studies
reported possible approaches to diﬀerentiate MSCs into ECs
[63, 64]. A previous study demonstrated that a 3D matrix
with tunable properties directed the diﬀerentiation of MSC
towards vascular cell types [64]. We also applied in situ
cross-linkable gelatin hydrogels by conjugating enzymati-
cally cross-linkable hydroxyphenyl propionic acid (GHPA)
(Figure 3) [63]. The 3D culture of MSCs in these hydrogels
induced vasculogenesis both in vitro and in vivo. Our results
showed that GHPA hydrogels induced spontaneous endo-
thelial diﬀerentiation of MSC without any soluble factors.
3.3. Surface Topography. When cells are cultured on bioma-
terial substrates, surface topography is known as a key reg-
ulator of cell behavior. Several previous studies reported
that surface topographical cues induced direct lineage spec-
iﬁcation of MSCs [66, 67, 70–72]. Microfeatures (40μm
line, 20μm spacing, and 1μm height) of ﬁbronectin strips
printed on a poly(lactic-co-glycolic acid) (PLGA) thin ﬁlm
were found to direct linage commitment of MSCs [66]. In
this study, modiﬁcation of MSCmorphology and cytoskeletal
arrangement on the patterned ﬁlm resulted in both neuronal
and myogenic lineages, even if myogenic diﬀerentiation was
dominant when the expression of functional proteins was
examined. Along the same line to direct MSC diﬀerentia-
tion, Lee et al. fabricated pseudo-3D microwells by templat-
ing a hydrazine-immobilized polyacrylamide gel displaying
inverse features of circular surface topography via PDMS
stamps (circular) [67]. As a result, small circular islands
induced an adipogenic phenotype of MSCs while anisotropic
geometries induced neurogenic diﬀerentiation. Micro- and
nanostructured titanium surfaces were used as potential
topographical cues to induce osteogenic diﬀerentiation of
MSCs [71, 72]. The nanotubule-shaped titanium oxide
surface structures, which have 70 to 100nm titanium oxide
nanotube arrays on them, induced cytoskeletal stress and
thereby directed osteogenic diﬀerentiation of MSCs [71].
It was also reported that osteoblastic diﬀerentiation of MSCs
was induced on the microstructured titanium surface (Ra =
3 22 μm) through α2β1 integrin-mediated interactions with
cocultured osteoblasts [72]. Our recent study determined
causative roles of topographical cues in directing lineage
speciﬁcation of MSC via patterned graphene surfaces with
additional evaluation of electrical stimulation as another
cue [70]. Our result showed that expression of osteoprogeni-
tor markers was increased by either (un)patterned graphene
substrate or electrical stimulation while the expression of
osteoblast makers was increased only when electrical stimu-
lation was applied together with the surface patterns.
4. Selection of Genetic Factor and Source Cell
Type for iPSC Reprogramming
Induced pluripotent stem cells (iPSCs) were introduced in
2006, which opened a new avenue for stem cell research
and regenerative medicine [73]. Obtaining an adequate
amount of stem cells is a major limitation for stem cell ther-
apy and research. Previously, classical methods employed to
induce pluripotency of somatic cells include somatic cell
nuclear transfer (SCNT) and cell fusion. However, limita-
tions associated with oocyte supply, low reprogramming eﬃ-
ciency, and phenotypic abnormalities of the produced animal
oﬀspring still hamper the widespread distribution of these
classical methods [74].
Resident stem cells in various tissues were also studied as
a promising source of stem cells, but the lack of appropriate
markers to deﬁne their phenotypes and their low diﬀerentia-
tion potential were considered as major hurdles for using
these cell sources. Hence, the breakthrough idea of repro-
gramming somatic cells with ectopic pluripotent markers
(Sox2, Oct3/4, Klf4, c-Myc, and Lin28) to eventually rep-
resent embryonic stem cell (ESC) characteristics was
undisputedly attractive [73]. However, it is still controver-
sial whether iPSCs possess the same pluripotency and dif-
ferentiation ability to ESCs. Donor cell-speciﬁc epigenetic
signatures remain even after reprogramming and thus gen-
erate problematic variations from the expected quality and
characteristics of iPSCs in terms of homogeneity and the
potential for maturation in stem cell therapy [75, 76]. More-
over, abnormalities created during the process of iPSC repro-
gramming, such as stablishing aberrant DNA methylation
patterns, were found to increase the heterogeneity in iPSCs
[77, 78]. Additionally, donor-speciﬁc genetic variations fur-
ther increase the heterogeneity of iPSC genetic proﬁling, such
as stablishing aberrant DNA methylation patterns.
4.1. Choice of Vectors for iPSC Reprogramming. Substantial
progress has been made in the methodologies to improve
the eﬃciency and eﬃcacy of reprogramming somatic cells
to iPSCs in the past decade (Table 4). The type of vectors
used to overexpress ectopic pluripotency factors within the
target cells are classiﬁed into integrating DNA vectors and
nonintegrating DNA free vectors. Integrating vectors are
further subclassiﬁed into insertional vectors including viral
and linear DNA delivery systems whereas insertion-free
transgene vectors include PiggyBac transposon [79, 80] and
plasmid/episomal vectors. Recently, nonintegrating systems
involving direct protein or microRNA vectors as well as var-
ious small molecules are used for reprogramming of somatic
cells into iPSCs [81, 82]. Integrating DNA vectors represent
an early generation tool for reprogramming and are still
commonly used in experiments owing to their high eﬃ-
ciency. Combinations of retroviral or lentiviral Sox2, Oct4,
Klf4, c-Myc, or Lin28 were most popularly used with or with-
out the use of transgene selection markers. Especially, these
ﬁrst-generation viral vectors possess the potential for ran-
dom insertional mutagenesis, but their undeniable high eﬃ-
ciency still renders them useful for a wide range of iPSC
research. Such random insertional mutagenesis contributes
to the unpredictability of iPSCs upon in vivo transplantation.
Viral promoter-driven ﬂuorescence and cre-LOX expression
systems have been used to track and control ectopic gene
expression but still generate insertional mutagenesis [83].
In order to overcome problems associated with mutagenesis
resulting from ectopic gene insertion, adenoviral, episomal,
or plasmid vectors were used as alternatives in the course of
developing the next generation of reprogramming methods
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[84, 85]. However, although these alternatives were less
prone to mutagenesis associated with ectopic gene integra-
tion, the major hindrance was the poor transfection eﬃ-
ciency, displaying eﬃciencies 1000–10,000 folds lower than
those of conventional viral vectors. Further improvement in
the reprogramming eﬃciency was achieved by applying
non-DNA methods using Sendai viral vectors, small mole-
cules, Lipofectamine, or miRNA transfections [86–90]. For
example, cell membrane-penetrating proteins were tagged
with Oct4, Sox2, Klf4, and c-myc for intracellular deliv-
ery and cell reprogramming. Human immunodeﬁciency
virus transactivator of transcription (HIV-TAT) protein
or polyarginine-tagged pluripotency factors were used to
derive mouse and human iPSC lines. However, its low
reprogramming eﬃciency still remains as a major hurdle
to overcome [91]. Together, the aforementioned noninte-
grating methods are promising to signiﬁcantly reduce
mutagenesis, but their reprogramming eﬃciencies need
to be enhanced further as the eﬃciencies are still considerably
lower (0.001%–) compared to integrating vectors (0.1%–1%).
Generating transgene-free iPSCs serves as an attractive
alternative because it can compensate for the low transfec-
tion eﬃciency. Addition of small molecules including his-
tone deacetylase (HDAC) inhibitors and other epigenetic
modiﬁers have been reported as representative examples
[92, 93]. On the other hand, the number of ectopic vectors
could be reduced by introducing supplementary compounds,
where inhibitors of G9a histone methyltransferase could
replace either Sox2, Oct4, or c-Myc during reprogram-
ming of neural progenitor cells (NPCs) and ﬁbroblasts in
mice [94]. The TGF-β receptor antagonist also signiﬁcantly
increased the reprogramming eﬃciency and kinetics in
murine [95, 96] and human ﬁbroblasts [97].
It needs to be investigated further whether the type of
vectors used to induce pluripotency contributes to the het-
erogeneity of produced iPSC lines or not. When retrovirus,
Sendai virus, and episomal vectors were used for iPSC gener-
ation, diﬀerent reprogramming strategies were applied to
obtain human iPSCs. As a result, very similar global gene
expression proﬁles were displayed but subtle diﬀerences were
observed in the levels of gene expression, indicating that the
heterogeneity of produced iPSC lines resulted from clonal
signatures rather than the reprogramming method itself
[98]. However, even when iPSCs were generated from cells
of the same donor, characteristic aberrations in DNA meth-
ylation at the epigenomic level were shown to be dependent
on the choice of reprogramming factors [99].
As a summary, random DNA aberrations are most
notably caused by viral genome integration, leading to iPSC
heterogeneity and unpredictability. Thus, nonintegrating
systems should be primarily considered as a basic means
for diﬀerentiation strategies towards clinical applications.
4.2. Donor Cell Characteristics and Stemness. The origin and
quality of donor cells are also important factors to ensure
successful reprogramming results. In particular, easy access,
abundant quantity, and enough replenishment of donor cells
after harvesting should be considered when the target donor
source is selected.
Donor somatic cell-speciﬁc transcriptional and epigenetic
signatures signiﬁcantly contribute to the heterogeneity of eﬃ-
ciency and eﬃcacy in reprogramming and diﬀerentiation of
iPSCs (Table 5). The most widely used cell source for repro-
gramming into iPSCs is dermal ﬁbroblasts, most frequently
harvested from neonates as well as adults [73]. Keratinocytes
(a type of bone marrow cells), peripheral blood cells (a type
of CD34+ peripheral blood mononuclear cells), amniotic ﬂuid
cells, cord blood stem cells, endometrial stromal ﬁbroblasts,
and dental pulp cells have been reported as reliable sources
of somatic cells for reprogramming (Figure 4) [100–106].
Moreover, it has been reported, even in cells which were orig-
inated from the same donor but from diﬀerent organs, that
the tissue-speciﬁc epigenetic signatures aﬀect the heteroge-
neity of eﬃciency and eﬃcacy in reprogramming and the
diﬀerentiation potential of iPSC lines. Such observations
were prominent in the early passages when the reprogram-
ming process is not yet complete [107–109].
If stemness is enhanced, the negative eﬀect of tissue-
speciﬁc epigenetic signature may be attenuated during the
process of serial passaging while losing the epigenetic mem-
ory sequentially. Characteristic DNA methylation patterns
are originated from the donor cells and thus can be tracked
in speciﬁc iPSC clones. Consequently, limitations in stem-
ness of iPSCs as opposed to the full pluripotency of embry-
onic stem cells are inevitable. Experimental techniques to
overcome the gap between the epigenetic memory of the
donor cell and the stemness of the derived iPSC lines have
been described in previous studies [110, 111]. One strategy
is to increase the iPSC passage number while another
approach is to introduce chromatin-modifying substances,
which diminishes the epigenetic memory and enhances
stemness. The process of acquiring pluripotency may not be
complete upon immediate silencing expression of exogenous
pluripotency factors but may continue for several rounds of
cell passaging. iPSCs exhibit considerable diﬀerences in their
telomere length and the global pattern of transcription and
DNA methylation [110, 112, 113]. On the other hand,
transgenes are usually silenced in the process of reprogram-
ming by de novo methylation. When this process is not
fully accomplished, gaining the pluripotency of the repro-
grammed cells primarily relies on the exogenously intro-
duced factors. When the endogenous pluripotent genes
are halted from being fully expressed, these colonies are
deﬁned as “partially reprogrammed.” Within such colonies,
pluripotency is frequently not fully acquired even after the
exogenous factors are eventually turned oﬀ [114, 115]. Con-
versely, when ectopic transgenes are not silenced and
exposed to residual activities or reactivation of the viral trans-
genes in the iPSC cells, tumor formation occurs as demon-
strated in chimera experiments [73]. Other potential causes
of epigenetic diﬀerences have also been attributed to either
aberrant or incomplete reprogramming or even by various
cell culture conditions [77, 116–119].
5. Conclusion
Although a growing body of evidence suggests stem cells as a
promising candidate for cell therapy in the position of
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replacing somatic cells, the aforementioned issues regarding
senescence and low diﬀerentiation eﬃciency must be
addressed for successful clinical applications. In this review,
we introduced state-of-the-art methods which are currently
approached to improve eﬃciency and eﬃcacy of stemness
maintenance, direct diﬀerentiation, and iPSC reprogram-
ming, with the minimal use of expensive and side eﬀect-
occurring growth factors. Biophysical stimulation, organic
compound treatment, genetic transfection, and various types
of biomaterials were employed to achieve the purposes. In
particular, the eﬀects of matrix stiﬀness, improving cell-cell
interaction, and antioxidant treatment became a major
part of interest. Additionally, biomaterials with speciﬁc
composition, stiﬀness, and topography can serve as a
promising toolbox to guide direct diﬀerentiation of stem
cells. Finally, several combinations or individual uses of
genetic factors to induce reprogramming of somatic cells
were introduced as a means of generating iPSCs. Pros
and cons of major reprogramming methods were dis-
cussed as well. Taken together, selection of biomaterials or
other external factors needs to be customized for target-
speciﬁc developments and application of stem cell therapy
towards successful clinical applications.
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